Corteva misses Q4 revenue expectations

Reuters
02/04
Corteva misses Q4 revenue expectations

Overview

  • Agriculture firm's Q4 revenue missed analyst expectations

  • Operating EBITDA for Q4 decreased 15% yr/yr

  • Company remains on track for planned separation in H2 of 2026

Outlook

  • Corteva expects 2026 operating EBITDA to be $4.0 bln to $4.2 bln

  • Company anticipates 2026 operating EPS of $3.45 to $3.70 per share

  • Corteva sees mixed global agriculture outlook with pricing pressures in key regions

Result Drivers

  • SEED TECHNOLOGY - Demand for latest technology and productivity improvements drove Seed performance

  • CROP PROTECTION VOLUME - Volume growth in new products and biologicals supported Crop Protection results, despite pricing pressure

  • CASH GENERATION - Robust cash generation driven by earnings growth and efficient working capital management

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Miss

$3.91 bln

$4.24 bln (15 Analysts)

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the agricultural chemicals peer group is "buy"

  • Wall Street's median 12-month price target for Corteva Inc is $80.00, about 9.3% above its February 2 closing price of $73.20

  • The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release: ID:nPn8PQYzKa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10